Studies have shown that neuroinflammation is considered a key factor in the progression of stroke and is of great importance during candidate drug screening for alternative treatments for IS.[37] The HBP1 TF downregulates the expression of HMGB1 and its related TLR4 and NF-κB, which has a protective effect against MI.[38]. Here, TLR4 is linked to stroke disorder.